Angiotensin II receptor blocker partially ameliorated intrarenal hypoxia in chronic kidney disease patients: a pre-/post-study
Angiotensin II receptor blocker partially ameliorated intrarenal hypoxia in chronic kidney disease patients: a pre-/post-study
复制标题
DOI：
10.1111/j.1445-5994.2011.02610.x
复制
发表时间：
2012-04-01
影响因子：
2.1
通讯作者：
Eiam-Ong, S.
中科院分区：
文献类型：
--
作者：
Manotham, K.;Ongvilawan, B.;Eiam-Ong, S.
慢性肾内缺氧被认为是进行性肾损害的致病因素。然而，缺乏可用的人类数据阻碍了这一领域的进展。在这项工作中，血氧水平依赖性磁共振成像被用来确定肾内氧状态之前和之后的血管紧张素受体阻滞剂（奥美沙坦）治疗正常人，糖尿病慢性肾脏疾病（CKD）患者和非糖尿病CKD患者。代表肾内氧合的平均R2* 在对照组中显著低于CKD组（12.42 +/- 0.53 /s vs 18.89 +/- 3.15 /s，P < 0.01），表明CKD患者存在肾内缺氧。奥美沙坦治疗诱导CKD患者的平均R2* 下降16.2 +/- 7.7%，表明该药物具有肾内缺氧改善作用。
Chronic intrarenal hypoxia has been regarded as a pathogenic factor of progressive renal damage. However, the lack of available human data has impeded the progress in this field. In this work, blood oxygen level-dependent magnetic resonance imaging was used to determine intrarenal oxygen status pre- and post-angiotensin receptor blockade (olmesartan) treatment in normal subjects, diabetic chronic kidney disease (CKD) patients and non-diabetic CKD patients. The mean R2*, which represents intrarenal oxygenation, was significantly lower in the control group than in the CKD group (12.42 +/- 0.53 /s vs 18.89 +/- 3.15 /s, P < 0.01), indicating the presence of intrarenal hypoxia in the CKD patients. The olmesartan treatment induced a 16.2 +/- 7.7% decrement of the mean R2* in CKD patients, suggesting that this drug had an intrarenal hypoxia ameliorating effect.